Cougar Biotechnology's Unattributed VC Round

Cougar Biotechnology raised a round of funding on April 17, 2006.

Cougar Biotechnology aims to in-license and develop oncology drugs. Cougar's oncology portfolio includes CB7630, a targeted enzyme inhibitor, which is currently being tested in Phase II clinical trial…

Articles about Cougar Biotechnology's Unattributed VC Round: